The Avacta Group share price (LSE: AVCT) is currently trading at 72.27p as of March 17, 2026, marking a 1.78% increase in the most recent session following the official opening of the Phase 1 trial for its second clinical candidate, AVA6103. With a market capitalization of approximately £321.5 million, Avacta is at a critical juncture in its transition to a pure-play oncology therapeutics company. Investors are currently focused on two primary catalysts: the imminent enrollment of the first patient in the AVA6103 “FAP-Exd” trial and the anticipated H1 2026 data readouts for AVA6000 in Triple Negative Breast Cancer (TNBC). The company’s financial position has stabilized following a £16 million fundraise in late 2025 and the deferral of convertible bond repayments to late 2027, providing a clear cash runway into Q3 2026. Analyst consensus remains bullish on the proprietary preCISION platform’s ability to reduce systemic chemotherapy toxicity, with recent data showing a 90% disease control rate in salivary gland cancer patients.
Current Market Status and 2026 Valuation
As of March 17, 2026, Avacta (LON: AVCT) is demonstrating renewed momentum. The stock has successfully built a base above 70p, a psychological level that had previously acted as resistance during the early 2026 trading sessions.
Key Trading Metrics
The current 52-week range of 26.00p to 84.00p reflects the high-beta nature of the UK biotech sector. Today’s trading volume of over 2.2 million shares indicates heightened investor interest following the March 16 announcement regarding the Phase 1 study opening for AVA6103 in the United States.
Valuation and Market Cap
With approximately 440.42 million shares outstanding, Avacta’s market cap of £321 million positions it as a mid-sized player in the AIM-listed life sciences space. Valuation is increasingly driven by “sum-of-the-parts” analysis as the company winds down its non-core diagnostics segment to focus entirely on its clinical pipeline.
AVA6000 (Faridoxorubicin) Program Progress
AVA6000 remains Avacta’s lead asset. It is a tumor-activated form of doxorubicin designed to concentrate the chemotherapy payload within the tumor microenvironment while sparing healthy tissue, specifically the heart.
Clinical Update 2026
In February 2026, Avacta received regulatory approval to remove the maximum cumulative dosing limit for AVA6000. This is a significant milestone, as conventional doxorubicin is limited by permanent cardiotoxicity. Patients in the current trial have received nearly 4x the standard cumulative dose without showing severe cardiac toxicity.
Efficacy in SGC and TNBC
Data released in late 2025 and updated in Q1 2026 confirmed a 90% disease control rate in salivary gland cancer (SGC). The market is now awaiting the H1 2026 data release for the Triple Negative Breast Cancer (TNBC) cohort, which is expected to be a major share price catalyst.
AVA6103: The Second Clinical Candidate
On March 16, 2026, Avacta officially announced the opening of clinical sites for its second oncology pipeline asset, AVA6103. This drug utilizes the preCISION platform to deliver exatecan, a potent topoisomerase I inhibitor.
Phase 1 Study Design
The Phase 1a dose-escalation study is evaluating AVA6103 in patients with advanced solid tumors, specifically:
Pancreatic Cancer
Gastric and GEJ Cancers
Small Cell Lung Cancer (SCLC)
Cervical and Vulvar Cancer
Strategic AI Collaboration
The indications for AVA6103 were selected using AI-driven analysis in collaboration with Tempus AI. This approach aims to identify patient populations where the Fibroblast Activation Protein (FAP) is most highly expressed, theoretically maximizing the drug’s activation and efficacy.
Financial Health and Cash Runway
Avacta’s management has taken aggressive steps in 2025 and 2026 to ensure the company remains funded through its next set of clinical readouts.
Cash Balance and Funding
As of December 31, 2025, Avacta reported unaudited cash and cash equivalents of £16.9 million. Following the £16 million equity raise in October 2025, the company has explicitly stated its cash runway extends into Q3 2026, covering the costs of both AVA6000 and AVA6103 trials.
Convertible Bond Deferral
A major “overhang” on the share price was addressed by deferring the quarterly convertible bond repayments originally due in early 2026. These payments are now deferred until October 2027, significantly reducing near-term cash outflows and the risk of equity dilution from bond conversions.
The preCISION Platform vs. ADCs
Avacta’s core value proposition lies in its preCISION platform. Unlike traditional chemotherapy, which is systemic, or Antibody Drug Conjugates (ADCs), which are complex to manufacture, preCISION offers a unique “sustained release” mechanism.
Key Advantages
Extended Half-Life: preCISION conjugates are designed to circulate longer than traditional small molecules.
Tumor Specificity: The payload is only released when it encounters FAP, a protein found in over 90% of solid tumor stroma.
Reduced Toxicity: By keeping the toxin “locked” in the blood, preCISION minimizes the hair loss, mouth sores, and heart damage typically associated with chemotherapy.
Practical Information for Investors
Trading LSE: AVCT
Avacta Group is listed on the London Stock Exchange’s AIM market.
Ticker Symbol: AVCT
Currency: Pence (GBX)
Trading Hours: 08:00 – 16:30 GMT
ISIN: GB0006212351
How to Stay Informed
Investors should monitor the London Stock Exchange’s Regulatory News Service (RNS) for clinical updates. The company also hosts “Avacta Academy” webinars to explain its science to retail shareholders.
FAQs
What is the current Avacta share price?
As of March 17, 2026, the Avacta share price is 72.27p.
What does AVA6000 do?
AVA6000 is a tumor-activated chemotherapy (doxorubicin) that targets the tumor microenvironment to reduce the toxic side effects of standard chemo.
When is the next data readout for Avacta?
Avacta is expected to release data for its Triple Negative Breast Cancer (TNBC) cohort in the first half of 2026.
Does Avacta still have a diagnostics business?
No, Avacta has transitioned to a pure-play therapeutics focus, having disposed of its non-core diagnostics assets (like Launch Diagnostics) in 2024–2025.
What is the 52-week high for AVCT shares?
The 52-week high is 84.00p, set in December 2025.
What is AVA6103?
AVA6103 is Avacta’s second clinical-stage drug, which delivers the potent payload exatecan using the preCISION platform.
How much cash does Avacta have?
As of the 2025 year-end update, Avacta had approximately £16.9 million in cash.
Who is the CEO of Avacta?
The CEO of Avacta is Christina Coughlin, MD, PhD, who took over to lead the company’s clinical oncology strategy.
Is the Avacta convertible bond a risk?
The risk has been mitigated by deferring repayments until October 2027, though the bond remains a long-term liability.
What is FAP?
FAP stands for Fibroblast Activation Protein, a protein found in the stroma of most solid tumors that acts as the “key” to unlock Avacta’s preCISION drugs.
Can I buy Avacta shares in an ISA?
Yes, Avacta is a UK-listed company and is fully eligible for Stocks and Shares ISAs and SIPPs.
For More business Related insights click on :
NatWest Group Share Price: Expert Analysis and 2026 Forecast
Next Share Price: Comprehensive 2026 Investor Analysis and Forecast
To read more ,New Castle Reporter